Déclion Holdings

Declion Holdings is a biotechnology company pioneering a new approach to treating neurodegenerative diseases by targeting the brain's glycome. The company's research focuses on Advanced Glycation End-products (AGEs), which are sugar-derived modifications that cause proteins like amyloid-beta to become more toxic and resistant to clearance. Through its proprietary platform, Declion is developing small molecule inhibitors designed to prevent these harmful cross-links and reduce neuroinflammation. This strategy aims to address the underlying drivers of Alzheimer's disease rather than just the symptoms. The company was founded by leading neuroscientists from Massachusetts General Hospital and Harvard Medical School.